NCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
Clinical Trials
28 trialsNCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
NCT04382664 2025-01-14
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Ultimovacs ASA
Phase 2 Completed
NCT01784913 2024-12-16
UV1/hTERT2012P
Ultimovacs ASA
Phase 1/2 Completed
NCT01789099 2024-12-16
UV1-hTERT2012L
Ultimovacs ASA
Phase 1/2 Completed
NCT02275416 2024-12-16
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
Phase 1/2 Completed
NCT01266083 2024-11-19
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Phase 2 Completed
NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
NCT01827137 2024-09-19
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
Phase 1/2 Completed
NCT05771584 2024-07-10
Conerstone3
Aston Sci. Inc.
Phase 2 Recruiting
NCT04713371 2024-05-09
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Rampart Health, L.L.C.
Phase 2 Active not recruiting
NCT02297698 2023-12-12
HER3+
Cancer Insight, LLC
Phase 2 Completed
NCT05284214 2023-09-15
SALIENT
Partner Therapeutics, Inc.
Phase 2 Withdrawn
NCT05794659 2023-07-20
Cornerstone4
Aston Sci. Inc.
Phase 2 Not yet recruiting
NCT02978222 2022-12-15
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Marker Therapeutics, Inc.
Phase 2 Terminated
NCT02873819 2022-03-08
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Gliknik Inc.
Phase 2 Completed
NCT02383212 2020-01-27
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Completed
NCT02149225 2018-08-07
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Immatics Biotechnologies GmbH
Phase 1 Completed
NCT00458601 2018-01-16
ACT III
Celldex Therapeutics
Phase 2 Completed
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT01265901 2017-10-12
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH
Phase 3 Completed
NCT01909752 2017-07-06
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
UbiVac
Phase 2 Completed
NCT02520102 2017-04-20
Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia
Sanofi
Phase 2 Withdrawn
NCT01479244 2017-02-27
PRESENT
Galena Biopharma, Inc.
Phase 3 Completed
NCT02240537 2016-04-19
BBMPI03
Benovus Bio, Inc.
Phase 1 Unknown
NCT00308087 2013-12-27
PREMIER
Sanofi
Phase 2 Terminated
NCT00785122 2013-05-16
IMA910-101
Immatics Biotechnologies GmbH
Phase 1/2 Completed
NCT00523159 2012-07-10
IMA901-202
Immatics Biotechnologies GmbH
Phase 2 Completed